Heart failure patients vindicate the name of Vericiguat: This drug is a real fighter!

On July 22, 2021, the European Union approved the marketing of Vericiguat under the trade name Verquvo. Veliciguat is an enzyme-stimulating drug that reduces the risk of cardiovascular death and hospitalization for heart failure (HF) due to or requiring treatment for heart failure as an outpatient intravenous diuretic by less than 45% in adults with symptomatic chronic heart failure.

Heart failure is a cardiovascular disease with a higher mortality rate, even higher than some malignant tumors. More than half of patients will die within five years of diagnosis. With the advent of aging, my country is about to become the country with the largest group of heart failure patients in the world. Therefore, there is an urgent need for an effective drug for treatment. The following will analyze whether it can be "qualified" for this arduous task in terms of its mechanism of action, safety and efficacy.

1 Mechanism of action: Inject energy into the failing heart!

The fundamental cause of heart failure is that the patient's heart has a disorder in systole or diastole, resulting in insufficient return of blood to the heart, and a large amount of blood accumulation in the arterial system. Under this influence, the heart will suffer from various circulatory problems. "To untie the bell, you must tie the bell." The key to the problem is the patient's heart systolic or diastolic disorder. Can veliciguat be an effective solution?

Veliciguat acts as a stimulator of soluble guanylate cyclase (sGC), which catalyzes the intracellular synthesis of cyclic guanosine monophosphate (cGMP), a second messenger that plays a role in the regulation of vascular tone, cardiac contractility, and cardiac remodeling. Heart failure is associated with impaired NO synthesis and reduced sGC activity, which may lead to myocardial and vascular dysfunction. By directly stimulating sGC, independently of and synergistically with NO, vericiguat increases intracellular cGMP levels, leading to smooth muscle relaxation and vasodilation. Therefore, veliciguat can treat heart failure at the root of the problem.

2 Safety and efficacy: Talking on paper is useless, let’s see how it goes in actual combat!

Veliciguat, a soluble guanylate cyclase (sGC) agonist, is the first drug indicated for the treatment of patients with exacerbating chronic heart failure. It is also the first chronic heart failure treatment approved for patients who are hospitalized for heart failure or require IV diuretics, based on results from the pivotal Phase 3 veliciguat trial and subject to a priority regulatory review.

The approval was supported by results from a Phase 3 clinical trial of a drug called vericiguat. This trial is specifically for patients with heart failure. Data from veliciguat has been published in the New England Journal of Medicine. The results at a median follow-up period of 10.8 months showed that the velicigat treatment group reduced the risk of the composite end point of hospitalization for heart failure and death from cardiovascular causes compared with the placebo group (35.5% vs 38.5%, HR=0.90, P=0.02). The data proves that Veliciguat can fully exert its efficacy while ensuring safety.

Directly pointing to the key mechanism of action of the problem ensures that Veliciguat is an effective drug, and accurate clinical trial data proves that Veliciguat is a "real-life combatant." It is believed that the emergence of Vericiguat will be a powerful "cardiac booster" for patients with heart failure. Where can I buy such good medicine? Medical Companion Travel will provide you with professional and reliable channels for purchasing medicines. Please consult customer service for details.